Chapter 153 : The New Case

Dr. Ayasha Rowe arrived at 9 AM on a Tuesday in January.

She was forty-one, wearing a coat that had been functional rather than fashionable, carrying a banker's box that she'd clearly carried through the lobby herself rather than asking the building's security desk to hold it. Her composure had the quality I'd learned to recognize in whistleblowers — not calm, something more deliberate than calm. The composure of a person who has been carrying something heavy for a long time and has made peace with the carrying because the alternative was worse.

Sarah Chen showed her to the conference room and came to my doorway: "She says she has documentation of manipulated clinical trial data at Meridian Pharmaceuticals."

I set down the Whitmore deposition I'd been reviewing.

"Who've her other meetings been with?"

"Sullivan & Cross and Hartley Partners. Both turned her down — pharmaceutical clients."

Conflicts. Standard.

"I'll be there in five minutes," I said.

I got there in three.

Dr. Rowe had her documents organized by date, which was the organizational instinct of a scientist rather than a lawyer: everything in chronological sequence, the story told by the evidence in the order it occurred. A different approach from what I'd have used. Better, in some respects.

She talked for ninety minutes.

The drug was Corvalox — a blood pressure medication that had completed Phase III clinical trials in 2013, received FDA approval in March 2014, and had been on the market for eight months. Market penetration was substantial: forty-seven thousand prescriptions filled in the first six months.

The problem was in the adverse event data.

During the Phase III trial, forty-three participants had experienced cardiac events — arrhythmias, one incident of atrial fibrillation, two hospitalizations. Under FDA Good Clinical Practice standards and the trial protocol, all forty-three events should have been classified as serious adverse reactions linked to the drug and submitted to the FDA as part of the safety data package.

Instead, thirty-one of the forty-three events had been reclassified. Eleven as "unrelated to study drug" — categorized as pre-existing conditions. Twenty as "minor adverse events" rather than serious ones. Two events had been excluded from the submission entirely, listed in an internal database marked for archive rather than regulatory submission.

The reclassification hadn't been an accident or an interpretive dispute.

Dr. Rowe had the emails.

Three consecutive message chains involving the trial's principal investigator, the company's chief medical officer, and the regulatory affairs director, in which the reclassification criteria were discussed, debated, and ultimately directed from above. The language was careful — they'd been careful people — but the meaning was unambiguous. The safety data was being shaped around the approval decision rather than the approval decision being made based on the safety data.

"The real adverse event rate," Dr. Rowe said, "predicts a cardiac risk elevation of approximately one point four percent in the patient population. That's roughly one in seventy patients. At current prescription volume, between four hundred and six hundred people currently taking Corvalox are at elevated cardiac risk."

I had been taking notes throughout. I stopped.

"How long have you had this?" I said.

"I discovered the reclassification database in June. I spent three months documenting it before I went to anyone internally." She looked at her hands. "I went to the chief compliance officer in September. He told me my concerns had been reviewed and addressed. I asked for documentation of the review. I never received it." A pause. "In October, I was informed that my position was being restructured. I retained my salary but lost my trial oversight responsibilities. Effectively sidelined." She looked at me steadily. "I have a non-disclosure agreement that was presented to me in connection with the restructuring. I signed it before I understood what I was signing."

"The NDA is not your primary concern. Whistleblower protection statutes take precedence over NDAs for safety-related disclosures." I looked at the documents. "What do you want to happen?"

"I want the FDA to have the real data," she said. "I want Corvalox either reformulated, restricted to a narrower patient population, or pulled from market pending review. And I want—" She stopped. The controlled composure shifted slightly, something more personal underneath it. "I want the people who made those decisions to be accountable for them. Not just regulatory consequences. Accountable."

I looked at her.

"We'll take the case," I said.

[ Win Rate Calculator: Meridian Pharmaceuticals — whistleblower case. Opposing counsel: Covington & Hargrove, pharmaceutical defense specialists. Budget differential: 15:1 against Zane & Roden. Regulatory complexity: high. Probability of favorable outcome: 44%. ]

I ran the full assessment in the afternoon, after Dr. Rowe had left with a client engagement letter signed and her case files copied into our system.

Forty-four percent.

The Hessington trial had started at sixty-one percent. The Forstman defense had been at thirty-eight. The Mike plea had started at thirty-four.

Forty-four was not good. It also wasn't the starting point that mattered — the ending point was what you built toward.

[ Argument Crusher: Meridian defense vectors — preliminary analysis. 12 potential defense arguments. Strongest: (1) reclassification based on established clinical criteria, internal review process followed; (2) FDA conducted independent review before approval; (3) adverse events involved in reclassification were subject to legitimate clinical interpretation; (4) whistleblower motivation — Dr. Rowe's position restructuring creates appearance of retaliation. Weakest: (8) broad industry practice argument; (11) claim that Dr. Rowe lacks statistical credentials. ]

The weakest arguments were the ones I could destroy quickly. The strongest ones required preparation.

Defense vectors four and one were the real targets: if Covington & Hargrove established that the reclassification was consistent with accepted clinical criteria and that Dr. Rowe's motivation was personal rather than principled, they had a fighting case.

I needed two things immediately: an independent clinical trial methodology expert who could evaluate the reclassification decisions against objective standards, and a timeline establishing that Dr. Rowe's whistleblowing predated the restructuring rather than the other way around.

Dr. Rowe had mentioned going to the compliance officer in September. The restructuring had been announced in October. The timeline was favorable.

Zane's office at three PM.

He read Dr. Rowe's documentation for twenty-six minutes.

I'd been watching him read for long enough to recognize his patterns: fast through background, slower through exhibits, returning to specific pages when something caught his attention. He went back to the email chain twice.

"How many patients?" he said, when he looked up.

"Four to six hundred at elevated cardiac risk. Current prescription volume."

"The real adverse event data was available and suppressed."

"The emails document the decision chain. Three executives, specific language, the reclassification criteria discussed and directed." I paused. "It's not ambiguous."

"And she has the original data?"

"Separate database, archived rather than submitted. She has access credentials and timestamped exports."

Zane set the folder down. He looked at the window. The January afternoon was doing what January in New York did — grey and functional, the city running at baseline without seasonal assistance.

"What's the case cost?" he said.

"Twelve to eighteen months of litigation. Expert witnesses in clinical trial methodology, pharmaceutical chemistry, FDA regulatory standards — we're looking at significant expert fees. Covington will file motions designed to make discovery expensive." I kept my voice level. "Contingency arrangement. Dr. Rowe can contribute to expenses but can't fund the full case."

"Revenue picture?"

"The AI class action settlement generated capital reserves. The two new clients from the Mike situation are stable revenue. We can absorb this case without compromising the firm's stability."

Zane looked at the folder.

"I built this firm," he said slowly, "because I believed the law should serve the people who need it, not just the people who can afford it in bulk." He looked at me. "You know this. I've said it before."

"You have."

"But there are different ways to believe something. You can believe it as a principle and represent it selectively. Or you can believe it as a practice and let it determine what cases you take even when the cases are expensive." He picked up the folder. "The AI class action was possible because we had resources. This case is possible because we built those resources. That's the design."

"That's the design," I agreed.

"Take it. Whatever you need."

I took the folder.

"Zane & Roden," I said. "It needs to mean something."

"It already does," he said. "You just keep adding to the definition."

I brought the case files home.

The kitchen table was the kitchen table — the specific ecosystem of our shared life, the surface that had held the wedding planning spreadsheets and Donna's Henderson documentation and my contingency research for Mike and the Barcelona sketches of Paulsen Consulting and about twelve hundred cups of coffee.

I spread Dr. Rowe's files across it.

Donna found me at midnight.

She came in from the bedroom in the robe she'd had since before I met her, which had survived the move and the engagement and the wedding and the honeymoon and was now a permanent fixture of our apartment with the same settled quality as everything else we'd kept.

She looked at the files.

"Clinical trial data?" she said.

"FDA submission manipulation. Blood pressure medication. Four to six hundred patients at elevated cardiac risk."

She sat down beside me without being asked, pulled a data table toward her, and looked at it with the pattern-recognition focus she brought to any document that was organized around information she could evaluate.

"These adverse events are listed as unrelated to study drug," she said, pointing. "But the timestamps—"

"Put them within the Phase III trial window," I said. "Yes."

"The reclassification wasn't based on clinical criteria. It was based on timing management."

"That's what Dr. Rowe says. I need an independent clinical methodology expert to confirm it."

She pulled another page. The email chain. She read three exchanges.

"This is bad," she said.

"Yes."

"And you're going to do something about it," she said.

Not a question. The statement of someone who had watched me build a career on exactly that proposition and knew it was settled.

"Yes," I said.

She reached across the table and reorganized the files into two stacks — the evidentiary documentation in one, the procedural history in the other. The same instinct that had sorted the HR documents at 2 AM during the Hessington trial. Different case, same mind, same partnership.

"Tell me about the opposing counsel," she said.

I told her.

We worked until two AM.

The case would take twelve months at minimum. Covington & Hargrove would file motions designed to exhaust resources and delay revelation. The FDA review process moved at the speed of federal bureaucracy, which was its own specific kind of slow. Between now and any resolution, somewhere between four and six hundred people were taking a medication that put them at elevated cardiac risk because a pharmaceutical company had decided approval was worth the reshaping of data.

That was the weight.

That was also the reason.

I looked at Donna across the kitchen table — my wife, who had found the memo that saved the Hessington trial and built her own career from scratch and said to anyway across a restaurant table in DUMBO and never once asked me to be less than exactly what I was.

"This is our design," I said.

She looked at me.

"Two people who build separately," I said. "And help each other when it matters."

She picked up a data table and continued reading.

"File number?" she said.

"ZM-2015-003."

"Dr. Rowe's first meeting with us was today?"

"This morning."

She organized the last stack of documents by date.

"Then we start tomorrow," she said.

The January night was outside. Manhattan was doing its permanent thing — lit and restless and indifferent to anyone's case timeline or probability assessment. In here, at a kitchen table covered in clinical trial data, two people were beginning the work that came after everything else had been built.

The odds were forty-four percent.

The cause was just.

Scott Roden opened the case file and started building.

A LOT More chapters reign FREE upon unwrittenrealm.com.

• Normal | $8 — 15 chapters ahead

• Advanced | $11 — 20 chapters ahead

• Overlord | $19 — 25 chapters ahead, plus request a refinement (plot, character, system) on any of my novels

/TheFinex5

▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰

― DECREE ―

More chapters reign FREE upon unwrittenrealm.com.

The throne acknowledges.

▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰